International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

Pharmacological Reviews

Volumn 54, Issue 2, 2002, Pages 161-202

  Howlett, A C ^e   Barth, F ^a   Bonner, T I ^b   Cabral, G ^c   Casellas, P ^a   Devane, W A ^c   Felder, C C ^d   Herkenham, M ^b   Mackie, K ^f   Martin, B R ^c   Mechoulam, R ^g   Pertwee, R G ^h  

^a SANOFI   (France)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 2 METHYL 3 (2 MORPHOLINOETHYL) 5 METHOXYINDOLE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 ARACHIDONYLGLYCERYL ETHER; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 [2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL]CYCLOHEXANOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADENYLATE CYCLASE; ANANDAMIDE; CALCIUM CHANNEL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL DERIVATIVE; CYTOKINE; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; GLYCEROL ETHER; GUANINE NUCLEOTIDE BINDING PROTEIN; ICOSANOID; ION CHANNEL; JWH 051; JWH 139; L 759633; L 759656; MITOGEN ACTIVATED PROTEIN KINASE; O 1184; O 1238; O 1812; POTASSIUM CHANNEL; RIMONABANT; UNCLASSIFIED DRUG; WIN 54461; WIN 56098;

AMINO ACID SEQUENCE; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; MOLECULAR CLONING; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ANIMALS; CANNABINOIDS; HUMANS; INTERNATIONAL AGENCIES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TERMINOLOGY;

EID: 18444376760     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.54.2.161     Document Type: Review

References (441)

1. (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability
2. Retrieval of information after use of marihuana
3. Neurobiology of marijuana abuse
4. 1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo
5. 9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: A microdialysis study
6. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
7. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
8. Cannabinoid receptor mediated inhibition of excitatory synaptic transmission in the rat hippocampal slice is developmentally regulated
9. The effects of cannabinoids on the brain
10. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons
11. 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication
12. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes
13. 9-tetrahydrocannabinol discrimination in rats
14. Cannabinoid receptor agonists and antagonists
15. The development of cannabinoid antagonists
16. The peripheral cannabinoid receptor: Adenylate cyclase inhibition and G protein coupling
17. 9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase
18. 9-tetrahydrocannabinol
19. Modulation of the release of endogenous γ-aminobutyric acid by cannabinoids in the guinea pig ileum
20. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids
21. Antinociceptive (aminoalkyl)indoles
22. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
23. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
24. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: Autonomic nervous mechanisms
25. Cannabinoid receptors and the regulation of immune response
26. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
27. The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme
28. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors
29. Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways
30. Stimulation of cannabinoid receptor CB1 induces krox·24 expression in human astrocytoma cells
31. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions
32. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1
33. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: Involvement of both mitogen-activated protein kinase and induction of Krox·24 expression
34. Cannabinoid-receptor expression in human leukocytes
35. B receptor site distribution in the rat central nervous system
36. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain
37. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity
38. Regional differences in cannabinoid receptor/G-protein coupling in rat brain
39. Cannabinoid signaling in cultured rat cerebellar granule cells
40. 2 receptor messenger RNAs during embryonic development in the rat
41. 2 receptor
42. 1 receptor agonists in the mouse brain
43. Unsaturated side chain β-11-hydroxyhexahydrocannabinol analogs
44. Marijuana and cannabinoids: Effects on infections, immunity and AIDS
45. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum
46. Control of pain initiation by endogenous cannabinoids
47. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide
48. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation
49. 9-transtetrahydrocannabinol and a synthetic derivative on maze performance of rats
50. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation
51. 9-tetrahydrocannabinol in rats
52. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism
53. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein
54. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist
55. Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium
56. Behavioral effects of cannabinoid agents in animals
57. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: An in vitro electrophysiological study
58. 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis
59. 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex
60. 9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study
61. Role of cyclic AMP in the actions of cannabinoid receptors
62. Effects of anandamide on cannabinoid receptors in rat brain membranes
63. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1
64. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor
65. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens
66. Tetrahydrocannabinol inhibition of macrophage nitric oxide production
67. 9-tetrahydrocannabinol-induced responses and apparent agonist activity
68. 9-tetrahydrocannabinol
69. Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents
70. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities
71. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2
72. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat
73. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281
74. 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse
75. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine
76. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus
77. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus
78. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
79. Conformationally restrained analogues of pravadoline: Nanomolar potent enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor
80. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation
81. Expression of cannabinoid receptor mRNA in murine and human leukocytes
82. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity
83. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
84. Regulation of a neuronal form of focal adhesion kinase by anandamide
85. A novel probe for the cannabinoid receptor
86. Determination and characterization of a cannabinoid receptor in rat brain
87. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
88. Cannabinoid stereoisomers: Pharmacological effects
89. Biosynthesis and inactivation of endocannabinoids: Relevance to their proposed role as neuromodulators
90. 1 vanilloid receptor "hybrid" ligands
91. Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids
92. Neurobehavioral activity in mice of N-vanillylarachidonyl-amide
93. 2 receptor-mediated actions of anandamide in mouse brain
94. Leptin-regulated endocannabinoids are involved in maintaining food intake
95. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
96. Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids
97. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids
98. Structural requirements for cannabinoid activity
99. 1
100. A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain
101. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics
102. The neurobiology and evolution of cannabinoid signalling
103. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoyl ethanolamide
104. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction
105. Cannabinoid receptors and their endogenous agonists
106. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation
107. 2 receptors
108. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones
109. nY motif and the cysteines in the C-terminal juxtamembrane region of the CB2 cannabinoid receptor
110. 9-tetrahydrocannabinol in chimpanzees
111. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: An in vivo and in vitro study
112. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: Coupling to nitric oxide release
113. 9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors
114. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
115. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene
116. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
117. New class of potent ligands for the human peripheral cannabinoid receptor
118. Isolation, structure and partial synthesis of an active constituent of hashish
119. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors
120. Binding of the non-classical cannabinoid CP 55,940 and the diarylpyrazole AM251 to rodent brain cannabinoid receptors
121. Imaging the brain marijuana receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo
122. 2- channel current
123. Nucleotide sequence of a human cannabinoid receptor cDNA
124. Molecular cloning of a human cannabinoid receptor which is also expressed in testis
125. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum
126. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A
127. Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR141716A
128. 1 receptors
129. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2 and is potentiated by the cannabinoid antagonist, SR 141716A
130. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes
131. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374)
132. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices
133. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices
134. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
135. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain
136. s linkage to the CB1 receptor
137. 3H]noradrenaline from mouse cultured sympathetic neurons: Release-modulating heteroreceptors
138. 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys
139. 1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt
140. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide
141. 2 receptor
142. Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system
143. 35S]thio)-triphosphate binding assay in rat cerebellar membranes
144. 2-like cannabinoid receptors on peripheral nerve terminals
145. 2 cannabinoid receptor
146. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis
147. Ceramide: A new second messenger of cannabinoid action
148. Effects of cannabinoids on energy metabolism
149. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations
150. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus
151. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
152. 1 receptor
153. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor
154. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor
155. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes
156. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
157. Cannabinoid receptor localization in brain
158. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in shortterm memory associated with changes in task specific firing of hippocampal cells
159. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes
160. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)
161. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells
162. Comparative sequencing of the human CB1 cannabinoid receptor gene coding exon: No structural mutations in individuals exhibiting extreme responses to cannabis
163. A synaptic transmission in the hippocampus
164. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: A comparison with opioids
165. o to the inhibition of adenylyl cyclase in carotid artery smooth muscle
166. 9-tetrahydrocannabinol
167. AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain
168. 35S]GTPγS binding in the mouse brain
169. 9-THC and anandamide
170. Cannabinoid compounds and signal transduction mechanisms
171. Pharmacology of cannabinoid receptors
172. 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor
173. Non-classical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model
174. Cellular signal transduction by anandamide and 2-arachidonoylglycerol
175. i in the inhibition of adenylate cyclase by cannabimimetic drugs
176. 1 cannabinoid receptor and impair signal transduction
177. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons
178. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716
179. Cannabimimetic indoles, pyrroles and indenes
180. Design, synthesis and pharmacology of cannabimimetic indoles
181. 2 receptor
182. 2 receptor
183. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor
184. 1 receptors at synaptic terminals in cultured cerebellar granule cells
185. 1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons
186. 1 receptors on peripheral sympathetic nerves
187. 1 ligands in the isolated guinea-pig ileum
188. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles
189. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
190. 8-tetrahydrocannabinol in rats and pigeons
191. Dissociative and discriminative stimulus functions of cannabinoids/cannabimimetics
192. Discrimination stimulus properties of tetrahydrocannabinols and related drugs in rats and pigeons
193. 9-THC as a discriminative stimulus in rats and pigeons: Generalization to THC metabolites and SP-111
194. 9-THC and its interaction with naltrexone and catecholamine blockers in rats
195. Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter
196. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro
197. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation
198. The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1)
199. The discovery of nonclassical cannabinoid analgetics
200. Inhibition of the cAMP signaling cascade via cannabinoid receptors: A putative mechanism of immune modulation by cannabinoid compounds
201. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation
202. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism
203. 1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain
204. 1 receptors
205. 1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice
206. 1 receptor-deficient mice
207. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission
208. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus
209. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons
210. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange
211. A model for the study of cannabinoid actions in microglia
212. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand
213. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand
214. 9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-γ IL-12 and IL-12 receptor β2 responses to Legionella pneumophila infection
215. Determinants of translational fidelity and efficiency in vertebrate mRNAs
216. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells
217. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids
218. Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists
219. Endocannabinoids as cardiovascular modulators
220. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves
221. Aminoalkylindole binding in rat cerebellum: Selective displacement by natural and synthetic cannabinoids
222. 1-Alkyl-3-(1-naphthoyl)pyrroles: A new class of cannabinoid
223. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats
224. 2 cannabinoid, as potential ligands for the cannabinoid receptors
225. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand
226. Preparation of iodine-123 labeled AM251: A potential SPECT radioligand for the brain cannabinoid CB1 receptor
227. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists
228. 1 receptor
229. 1 receptor
230. 1 receptor knockout mice
231. New azacannabinoids highly active in the central nervous system
232. 2 receptor mRNA in mouse immune cell subpopulations and following B cell stimulation
233. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells
234. SR 141716A enhances spatial memory as assessed in a radialarm maze task in rats
235. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats
236. 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism
237. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs
238. Novel analogues of arachidonylethanolamide (anandamide): Affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability
239. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice
240. 8-THC-dimethylheptyl in mice and dogs
241. Functional CB1 cannabinoid receptors in human vascular endothelial cells
242. Cannabinoids. Structure-activity studies related to 1,2-dimethylheptyl derivatives
243. Localization of cannabinoid receptors and non-saturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids
244. Anandamide uptake by human endothelial cells and its regulation by nitric oxide
245. Anandamide hydrolysis by human cells in culture and brain
246. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells
247. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells
248. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor
249. 2 receptors
250. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors
251. Distribution of cannabinoid receptor messenger RNA in the human brain: An in situ hybridization histochemistry with oligonucleotides
252. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2
253. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus
254. 1 cannabinoid receptors
255. Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens
256. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain
257. 1 receptor knockout mice
258. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids
259. Behavioral, biochemical and molecular modeling evaluations of cannabinoid analogs
260. Marihuana-like activity of new synthetic tetrahydrocannabinols
261. Cannabinoid transmission and pain perception
262. Discovery and characterization of endogenous cannabinoids
263. Structural requirements for cannabinoid receptor probes
264. 2 receptors in the A9-tetrahydrocannabinol-induced inhibition of natural killer activity
265. Changes in rat spleen cannabinoid receptors after chronic CP-55,940: An autoradiographic study
266. Molecular aspects of cannabinoid receptors
267. Localization of cannabinoid receptor messenger RNA in rat brain
268. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
269. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system
270. 9-tetrahydrocannabinol modulates antigen processing by macrophages
271. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation
272. Adenylyl cyclase, a coincidence detector for nitric oxide
273. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
274. A random walk through a cannabis field
275. Cannabinoid geometry and biological activity
276. Structure-activity relationships in the cannabinoid series
277. Endocannabinoids
278. 1-tetrahydrocannabinol, the major active constituent of hashish
279. Stereochemical requirements for cannabinoid activity
280. Stereochemical requirements for cannabimimetic activity
281. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells
282. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain
283. A cannabinoid derived prototypical analgesic
284. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs
285. 1 cannabinoid receptor
286. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones
287. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons
288. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship
289. Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes
290. 2+ in endothelial cells
291. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release
292. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord
293. Molecular characterization of a peripheral receptor for cannabinoids
294. Molecular phylogenetics and the origins of placental mammals
295. 9-tetrahydrocannabinol (THC) on memory in the rat
296. 1 receptors
297. 9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration
298. 9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze
299. 2+ signals in cerebellar granule neurons in culture
300. Anti-CD40, anti-CD3 and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes
301. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals
302. Cannabinoid receptor genes
303. Aminoalkylindoles: Actions on specific G-protein-linked receptors
304. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells
305. Natural and synthetic endocannabinoids and their structure-activity relationships
306. 2+ channels in a neuronal expression system
307. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity
308. Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation
309. Potential therapeutic agents derived from the cannabinoid nucleus
310. Arachidonylethanolamide (AEA) activation ofFOS proto-oncogene protein immunoreactivity in the rat brain
311. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice
312. 9-tetrahydrocannabinol
313. 2 receptors
314. Pharmacology of cannabinoid receptor ligands
315. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development
316. Neuropharmacology and therapeutic potential of cannabinoids
317. Cannabinoids and the gastrointestinal tract
318. Cannabinoid receptors and pain
319. Cannabinoids and multiple sclerosis
320. 1 receptors in guinea-pig small intestine
321. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties
322. AM630, a competitive cannabinoid receptor antagonist
323. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens
324. Cannabinoid receptors and their ligands
325. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine
326. 3H]SR141716A
327. Cannabinoid receptor expression in immune cells
328. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid
329. Structural determinants for recognition and translocation by the anandamide transporter
330. The endocannabinoid system as a target for therapeutic drugs
331. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation
332. The endocannabinoid nervous system: Unique opportunities for therapeutic intervention
333. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist
334. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: Neurovascular regulation
335. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries
336. Structure-activity relationships in cannabinoids
337. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: Achievements and challenges
338. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase
339. Enhancement of memory in cannabinoid CB1 receptor knock-out mice
340. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes
341. Functional role of tryptophan residues in the fourth transmembrane domain of the CB2 cannabinoid receptor
342. 2 cannabinoid receptor
343. Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase
344. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
345. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor
346. Characterization of two cloned human CB1 cannabinoid receptor isoforms
347. 3H]-SR141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain
348. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens
349. Therapeutic aspects of cannabis and cannabinoids
350. A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization
351. Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus
352. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake
353. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine
354. 2 cannabinoid receptors of L759633, L759656 and AM630
355. Structure-activity relationship for the endogenous cannabinoid, anandamide and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
356. 8-tetrahydrocannabinol at cannabinoid receptors
357. 1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase
358. In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: Involvement of both CB1 and CB2 receptors
359. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes
360. 1 cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein Fan
361. 1 receptor-dependent G-protein activation in rat cerebellar membranes
362. Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system
363. Modulation of transmitter release via presynaptic cannabinoid receptors
364. Cannabinoid receptor-mediated inhibition of dopamine release in the retina
365. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus
366. 35S]thio)triphosphate binding in rat brain membranes
367. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
368. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons
369. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
370. 9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture
371. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor
372. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor
373. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
374. Erratum: An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
375. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands
376. 35S]GTPγS autoradiography in rat brain
377. 35S]thio]triphosphate binding
378. Inhibitory effects of SR141716A on G-protein activation in rat brain
379. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets
380. Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: Immunochemical characterization by fusion protein antibodies
381. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase
382. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
383. Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology
384. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2
385. 2
386. 2-Arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1
387. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia and human monocytes
388. Antagonism of LPS and IFN-γ induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase
389. Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release
390. Identification and characterization of the leech CNS cannabinoid receptor: Coupling to nitric oxide release
391. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice
392. Receptor-dependent formation of endogenous cannabinoids in cortical neurons
393. A second endogenous cannabinoid that modulates long-term potentiation
394. 2++ transient in NG108-15 cells
395. 2+ in neuroblastoma x glioma hybrid NG108-15 cells
396. Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells
397. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor: Structure-activity relationship of 2-arachidonoylglycerol ether-linked analogues and related compounds
398. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor: Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells
399. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
400. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons
401. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum
402. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata
403. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells
404. 1 opioid receptor mechanism
405. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling
406. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): Evidence for subtype specificity
407. Effects of nitric oxide on adenylyl cyclase stimulation in N18TG2 neuroblastoma cells
408. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA
409. Comparative receptor binding analyses of cannabinoid agonists and antagonists
410. 9-THC-DMH
411. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation
412. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues
413. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
414. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation
415. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry
416. The fatty acid amide hydrolase (FAAH)
417. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells
418. 9-THC on spatial reference and working memory in mice
419. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro
420. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro
421. 1 receptor-mediated inhibition of noradrenaline release in the guinea pig lung
422. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase
423. Mesenteric vasodilation mediated by endothelial anandamide receptors
424. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells
425. Pain modulation by release of the endogenous cannabinoid anandamide
426. The relative activity of various purified products obtained from American grown hashish
427. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide
428. 9-THC-induced antinociception
429. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A
430. The central cannabinoid receptor inactivation suppresses endocrine reproductive functions
431. Discriminative stimulus effects of anandamide in rats
432. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats
433. Structure-activity relationships ofindole- and pyrrole-derived cannabinoids
434. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys
435. 1 receptor recognition and activation
436. 9-tetrahydrocannabinol in rats and rhesus monkeys
437. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
438. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway
439. Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice
440. The anandamide transport inhibitor AM404 activates vanilloid receptors
441. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide